The immediate impact of 280E on price multiples of cannabis companies: PART I [1][2] February 20, 2024 Lane Bruns Banking, Finance & Real Estate, Cannabis Investments 0 Comments By Lane Bruns, CEO of ICANIVEST Executive Summary In this 4-part series, we define and analyze the appropriate price multiples to value cannabis companies with and without 280E. In Part 1, we discuss the nuances around using price multiple ratios… Read More→
The immediate impact of 280E on cannabis companies’ DCF valuations January 22, 2024 Lane Bruns Banking, Finance & Real Estate, Cannabis Investments, Uncategorized 0 Comments By Lane Bruns, ICANIVEST Executive Summary and Results This article identifies the variables in the DCF (discounted cash flow) valuation model that will immediately change if and when cannabis is rescheduled to a Schedule 3 or below drug. It also… Read More→
Measuring the Downstream Impact of 280e Removal October 30, 2023 Erik Ott News & Insights 0 Comments by Erik Ott With a glimmer of light at the end of the tunnel for a move from a Schedule 1 drug to a Schedule 3 drug the cannabis industry has begun to contemplate how the removal of 280e would… Read More→
A Prescription for Progress? September 21, 2023 Benton Bodamer Policy & Legal 0 Comments Would a Schedule III Reclassification of Psychoactive Cannabis Help or Hurt State Operators? By Benton Bodamer, Member, Dickinson Wright PLLC, Adjunct Professor of Law, Drug Enforcement and Policy Center, Moritz College of Law, The Ohio State University I. Introduction On… Read More→
Cannabis Taxation is Theft July 17, 2023 AggregatedNews Taxes 1 Comment By Griffen Thorne, Attorney at Harris Bricken Whether you’re the kind of person who wants to End the Fed, or the kind of person who wants to tax the rich like a Scandinavian nation, you’ll probably agree on one thing:… Read More→
Key Risks and Challenges Facing Cannabis Businesses Serving the Growing U.S. Market September 27, 2021 Lawrence Baye Accounting 0 Comments By Lawrence Baye, CMC, CISA and Mark Bednarz, CPA, CFE, CISA Cannabis has been in the headlines again as voters in many parts of the country approved its availability for recreational use during the last election cycle. Attention has shifted… Read More→
Cannabis M&A – A Template for Success Part 3: The Due Diligence Process December 14, 2020 Erik Ott Mergers & Acquisitions, Spotlight 0 Comments In the third of a 3-part series, Erik Ott of Investment Bank KO Acquisitions examines the due diligence process and shares advice on how to drive a transaction to a successful conclusion. In Part 1 Ott focused on the requirements… Read More→
Why We Love the Harborside IRC §280E Appeal June 15, 2020 AggregatedNews IRS 280E 0 Comments By Vince Sliwoski, Attorney at Harris Bricken Recently, I mentioned that except for Champ v. Commissioner, no cannabis company has ever won an IRC §280E case. One of the more famous setbacks was a 2018 case known as Harborside v.… Read More→
International Cannabis: Guidance for Companies Entering the U.S. Market, Part 2 – Taxation June 1, 2020 AggregatedNews International 0 Comments by Jonathan Bench, Attorney At Harris Bricken In prior blog posts (see here and here), I described how we have been fielding regular inquiries regarding international cannabis, both from companies inside the U.S. looking internationally and from international companies looking… Read More→
How to Convert a California Nonprofit Mutual Benefit Corporations to a For-Profit Corporation under Proposition 64 June 6, 2018 Ben Condon Banking, Finance & Real Estate 0 Comments Law Prior to 2018 - Non-Profit MBCs Ruled Medicinal cannabis businesses in California generally operated as nonprofit mutual benefit corporations prior to 2018. Although these medicinal cannabis businesses formally are incorporated as nonprofit mutual benefit corporations, they do not meet the requirements for income tax exemption described… Read More→